SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.

Src up-regulation is a common event in human cancers. In colorectal cancer, increased Src levels are an indicator of poor prognosis, and progression to metastatic disease is associated with substantial increases in Src activity. Therefore, we examined the activity of SKI-606, a potent inhibitor of Src and Abl kinases, against colon tumor lines in vitro and in s.c. tumor xenograft models. SKI-606 inhibited Src autophosphorylation with an IC(50) of approximately 0.25 micromol/L in HT29 cells. Phosphorylation of Tyr(925) of focal adhesion kinase, a Src substrate, was reduced by similar concentrations of inhibitor. Antiproliferative activity on plastic did not correlate with Src inhibition in either HT29 or Colo205 cells (IC(50)s, 1.5 and 2.5 micromol/L, respectively), although submicromolar concentrations of SKI-606 inhibited HT29 cell colony formation in soft agar. SKI-606 also caused loosely aggregated Colo205 spheroids to condense into compact spheroids. On oral administration to nude mice at the lowest efficacious dose, peak plasma concentrations of approximately 3 micromol/L, an oral bioavailability of 18%, and a t(1/2) of 8.6 hours were observed. SKI-606 was orally active in s.c. colon tumor xenograft models and caused substantial reductions in Src autophosphorylation on Tyr(418) in HT29 and Colo205 tumors. SKI-606 inhibited HT29 tumor growth on once daily administration, whereas twice daily administration was necessary to inhibit Colo205, HCT116, and DLD1 tumor growth. These results support development of SKI-606 as a therapeutic agent for treatment of colorectal cancer.

[1]  R. Bast,et al.  Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[3]  T. Yeatman,et al.  Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. , 2002, Cancer research.

[4]  V. Levin,et al.  Activity of pp60c-src in 60 different cell lines derived from human tumors. , 1994, Cancer biochemistry biophysics.

[5]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[6]  R. Bohacek,et al.  Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. , 2003, Current opinion in drug discovery & development.

[7]  S. Curley,et al.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. , 1993, The Journal of clinical investigation.

[8]  D. Fujita,et al.  Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells , 2002, BMC Biochemistry.

[9]  S. Zimmer,et al.  The effect of dibutyryl camp (dBcAMP) on morphological differentiation, growth and invasion in vitro of a hamster brain‐tumor cell line: A comparative study of dBcAMP effects in 2‐ and 3‐dimensional cultures , 1991, International journal of cancer.

[10]  M. Tang,et al.  Tyrosine Phosphorylation of Focal Adhesion Kinase Stimulated by Hepatocyte Growth Factor Leads to Mitogen-activated Protein Kinase Activation* , 1998, The Journal of Biological Chemistry.

[11]  F. Sirotnak.  Studies with ZD1839 in preclinical models. , 2003, Seminars in oncology.

[12]  G. McLean,et al.  Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling , 2002, Nature Cell Biology.

[13]  D. Boschelli,et al.  Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. , 2001, Journal of medicinal chemistry.

[14]  D. Fabbro,et al.  Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. , 2003, European journal of cancer.

[15]  S. Ashley,et al.  Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. , 2003, Surgery.

[16]  Fei Ye,et al.  7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. , 2004, Journal of medicinal chemistry.

[17]  A. Skoudy,et al.  Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin. , 1996, The Biochemical journal.

[18]  D. Sheppard,et al.  Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling , 2002, The Journal of cell biology.

[19]  M. Mareel,et al.  The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. , 2002, Cancer research.

[20]  A. Doherty,et al.  Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. , 2001, Journal of medicinal chemistry.

[21]  D. Cheresh,et al.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis , 2004, The Journal of cell biology.

[22]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[23]  A. Kraker,et al.  Src activation regulates anoikis in human colon tumor cell lines , 2002, Oncogene.

[24]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[25]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[26]  C. Staley,et al.  Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  T. Terao,et al.  Transforming Growth Factor-β1-dependent Urokinase Up-regulation and Promotion of Invasion Are Involved in Src-MAPK-dependent Signaling in Human Ovarian Cancer Cells* , 2004, Journal of Biological Chemistry.

[28]  Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. , 2001 .

[29]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[30]  D. Boschelli,et al.  2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. , 1998, Journal of medicinal chemistry.

[31]  Christopher C. Taylor,et al.  Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. , 2003, Biochemical and biophysical research communications.

[32]  D. Fabbro,et al.  SRC family kinases: potential targets for the treatment of human cancer and leukemia. , 2003, Current pharmaceutical design.

[33]  T. Hunter,et al.  Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases , 1996, Molecular and cellular biology.

[34]  Peter F Thall,et al.  Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. , 2003, Gynecologic oncology.

[35]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[36]  H. D. Showalter,et al.  Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. , 2000, Biochemical pharmacology.

[37]  D. Coppola,et al.  Coexpression of IGF-1R and c-Src Proteins in Human Pancreatic Ductal Adenocarcinoma , 2003, Digestive Diseases and Sciences.

[38]  J. Parsons,et al.  Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells , 2001, Oncogene.

[39]  Qiang Yu,et al.  Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis , 2004, Oncogene.

[40]  E. Parkinson,et al.  The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. , 2000, Molecular biology of the cell.

[41]  L. Ellis,et al.  Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src * , 1998, The Journal of Biological Chemistry.

[42]  J. Cherrington,et al.  Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. , 2003, Molecular cancer therapeutics.

[43]  S. Hanks,et al.  Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. , 1996, Biochemical and biophysical research communications.

[44]  M. Frame,et al.  Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.

[45]  H. Friess,et al.  Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. , 1998, Biochemical and biophysical research communications.

[46]  B. Sefton,et al.  Phosphorylation of a Src Kinase at the Autophosphorylation Site in the Absence of Src Kinase Activity* , 2000, The Journal of Biological Chemistry.

[47]  S. Hirohashi,et al.  Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  S. Curley,et al.  Site-specific differences in pp60c-src activity in human colorectal metastases. , 1993, The Journal of surgical research.

[49]  H. Xiao,et al.  Augmentation of metalloproteinase (gelatinase) activity secreted from Rous sarcoma virus-infected cells correlates with transforming activity of src. , 1995, Oncogene.

[50]  P. Johnston,et al.  The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. , 2003, Seminars in oncology.

[51]  A. Ryan,et al.  Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice , 2004, Clinical Cancer Research.